IR Archives - Page 2 of 32

Ziccum has appointed a nomination committee for the 2025 annual general meeting

The delegates have been appointed for the nomination committee in anticipation of Ziccum’s 2025 annual general meeting ("AGM").

Ziccum’s nomination committee for the annual general meeting 2025 has been appointed in accordance with the instructions for the nomination committee decided by the 2022 AGM.

The nomination committee consists of:
• Randy Rivera, Global Corporate Finance (“GCF”)
• William Lithander, own mandate
• Göran Conradson, own mandate

Shareholders who wish to submit proposals to the nomination committee are welcome to contact the nomination committee via letter to Ziccum AB, Scheelevägen 22, 223 63 Lund, Sweden or via e-mail to agm@ziccum.com no later than 28 February 2025.

The 2025 annual general meeting will take place on Tuesday, 27 May 2025.

About Ziccum

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.

Ziccum has appointed a nomination committee for the 2025 annual general meeting

Ziccum har utsett valberedning inför årsstämma 2025

Valberedningens ledamöter inför Ziccums årsstämma 2025 har nu utsetts.

Ziccums valberedning inför årsstämman 2025 har tillsatts i enlighet med instruktionen för valberedningen som beslutades av årsstämman 2022.

Valberedningen består av:
• Randy Rivera, Global Corporate Finance (“GCF”)
• William Lithander, eget innehav
• Göran Conradson, eget innehav

Aktieägare som vill lägga fram förslag till valberedningen är välkomna att kontakta valberedningen via brev till adress Ziccum AB, Scheelevägen 22, 223 63 Lund, Sweden eller via e-post till agm@ziccum.com senast fredagen den 28 februari 2025.

Årsstämman 2025 kommer att äga rum tisdagen den 27 maj 2025.

Om Ziccum

Ziccum utvecklar LaminarPace®, en unik metod för torkning av biologiska läkemedel och vacciner i rumstemperatur. Metoden bygger på massöverföring istället för värmeöverföring. Tekniken licensieras ut till utvecklare och tillverkare av vaccin och biologiska läkemedel inom den globala läkemedelsindustrin. Genom att minska den stress som den aktiva substansen utsätts för under torkningen erbjuder LaminarPace® en unik möjlighet att ta fram termostabila biologiska läkemedel med partikel-teknologi i en torr pulverberedning. Dessa är enkla att hantera och transportera och lämpar sig utmärkt för nya administreringssätt. Tekniken har framgångsrikt tillämpats på mRNA, peptider, proteiner, antikroppar, lipider och enzymer, samt på hjälpämnen och adjuvanter, och lämpar sig väl för industriell tillämpning. Ziccum är noterat på Nasdaq First North Growth Market.

Ziccum har utsett valberedning inför årsstämma 2025

Ziccum reports good progress in the project for inhalable mRNA/LNP

Ziccum AB (publ) (‘Ziccum’) has an ongoing project with Copenhagen University to engineer inhalable solid dosage forms of mRNA/LNP. At the production stage, all primary development objectives have been met. The project has reached the phase of animal testing, with several trials completed with good results.

The two main objectives of the study involve engineering of inhalable dry powder particles of mRNA/LNP materials with the precise activity and structure characteristics required for inhalation, and to then test the effectiveness of delivery to the lungs in animal studies. Through the efforts in this project, Ziccum is aiming to build a strong case for pharmaceutical companies that have an ambition to develop inhalable mRNA/LNP, an area that is rapidly becoming of high interest in respect to new vaccines and treatments.

The project is executed in collaboration with Copenhagen University together with Professor Camilla Foged, who is an international authority in vaccine design and delivery. Model messenger-RNA used in the project is formulated in lipid nanoparticles (LNPs). Production of dry powders based on these fragile LNP-formulations has been considered very challenging or even impossible with conventional manufacturing methods.

As reported earlier this year, Ziccum has generated an encouraging set of trial formulations with the precise desired powder properties for inhalation. These results have now been further complemented. Today, Ziccum can also report on several positive findings achieved in the project, as described below.

First stage: endpoints met and further complemented
The desired outcome in stage 1 related to particle morphology, structure and mass median aerodynamic diameter (MMAD). These are important metrics that describe the dry particle’s ability to ‘fly’ as an aerosol. The results demonstrate that LaminarPace® successfully produces inhalable particles with the correct MMAD and morphology.

These are very important results: other techniques to obtain dry powder have not generated materials of reliable quality, let alone with any acceptable particle characteristics. For example, freeze-drying will typically only produce a sticky cake of material. Now, additional formulation excipient compositions have been investigated in the project, for further advancement regarding delivery performance parameters.

Second stage: advanced in-vivo testing in good progress
The purpose of administering dry powder LaminarPace® material to mice is to verify that the active drug ingredient is correctly delivered to the mucosal barrier, transported through this barrier and resulting in the desired therapeutic effect. The mRNA activity is monitored with advanced image analysis of the fluorescence that is generated upon correct drug delivery effect.

The scope in this experimental stage has included one trial with intra-muscular injection in mice, where the LaminarPace® material has excellent initial results, fully preserving the mRNA activity.
A second animal trial has verified the delivery of LaminarPace® material to the lung via aerosol inhalation, showing correct delivery and uptake, demonstrating the desired therapeutic effect for the LaminarPace® material. The third animal study, currently on-going, is testing this also with dry powder materials.

Ziccum CEO Ann Gidner: “Having the ability to accomplish mRNA delivery through inhalation is a unique argument for LaminarPace®. Since the world-wide deployment of mRNA-based Covid vaccines, there has been a rapidly increasing interest in RNA-based drugs that are suitable for delivery by inhalation. This has resulted in multiple new business dialogues for Ziccum. With the current progress, we see several important topics to pursue further”.

To achieve inhalable Biopharmaceuticals and RNA/LNP treatments
Inhalable solid dosage forms of biological drugs and vaccines are of great interest to the pharmaceutical industry. Solid dosage forms may offer increased storage stability compared to liquid formulations, simplified handling and patient convenience, and very significant cost savings. Currently, there are no existing inhalable mRNA/LNP therapies on the market. The main reason is that the elevated temperatures of conventional drying methods are not applicable for processing of mRNA/LNP materials, since the active substances are highly sensitive to changes in temperature and other factors causing molecular stress. Ziccum’s technology LaminarPace® is applied at room temperature with minimal stress factors, enabling a very gentle treatment compared to other methods.

About Ziccum

Ziccum reports good progress in the project for inhalable mRNA/LNP

Kommuniké från extra bolagsstämma i Ziccum

Ziccum AB (publ) (”Bolaget”) avhöll den 12 november 2024 extra bolagsstämma i Lund. Vid stämman fattades bland annat följande beslut.

Ändring av bolagsordningen
Stämman beslutade, i enlighet med styrelsens förslag, att anta en ny bolagsordning. Den nya bolagsordningen innehåller ändrade gränser för aktiekapital respektive antal aktier för att möjliggöra den företrädesemission av units som styrelsen har för avsikt att besluta om enligt Bolagets pressmeddelande den 10 oktober 2024.

Emissionsbemyndigande
Stämman beslutade, i enlighet med styrelsens förslag, att bemyndiga styrelsen att, under tiden intill nästa årsstämma och utöver bemyndigandet som beslutades om vid årsstämman 2024, vid ett eller flera tillfällen fatta beslut om nyemission av aktier och teckningsoptioner. Nyemission av aktier och teckningsoptioner med stöd av bemyndigandet ska kunna ske med eller utan avvikelse från aktieägarnas företrädesrätt, mot kontant betalning, apport eller kvittning eller i annat fall på villkor som avses i 2 kap. 5 § andra stycket 1–3 och 5 aktiebolagslagen. Beslut om nyemission av aktier och teckningsoptioner med stöd av bemyndigandet ska kunna ske med högst det sammanlagda antal aktier och teckningsoptioner som kan ges ut utan ändring av den vid var tid av bolagsstämman antagna bolagsordningen.

Bemyndigandet avses bland annat användas för att genomföra den företrädesemission av units som styrelsen har för avsikt att besluta om enligt Bolagets pressmeddelande den 10 oktober 2024, vilket möjliggör Bolagets tekniska utveckling av LaminarPace® samt vidare affärsutveckling. Skälet till att nyemission av aktier och teckningsoptioner med stöd av bemyndigandet ska kunna ske med avvikelse från aktieägarnas företrädesrätt är för att möjliggöra för Bolaget att betala garantiersättning i form av units till garanter som lämnar garantiåtaganden i den företrädesemission som styrelsen avser besluta om med stöd av bemyndigandet.

Om Ziccum

Kommuniké från extra bolagsstämma i Ziccum

Bulletin from the extraordinary general meeting of Ziccum

The following main resolutions were passed at the extraordinary general meeting (the “EGM”) of Ziccum AB (publ) (the “Company”) on 12 November 2024 in Lund.

Amendment of the articles of association
The EGM resolved, in accordance with the board of directors’ proposal, to adopt new articles of association. The new articles of association contain changed limits for share capital and number of shares to enable the rights issue of units that the board of directors intends to resolve upon in accordance with the Company’s press release on 10 October 2024.

Issue authorization
The EGM resolved, in accordance with the board of directors’ proposal, to authorize the board of directors to, during the period until the next annual general meeting and in addition to the authorization resolved upon at the annual general meeting 2024, on one or more occasions resolve on a new issue of shares and warrants. New issues of shares and warrants by virtue of the authorization may be made with or without deviation from the shareholders’ pre-emption rights, against payment in cash, in kind or by way of set-off or otherwise on terms referred to in Chapter 2. Section 5, second paragraph, 1–3 and 5 of the Swedish Companies Act. Resolutions on new issues of shares and warrants by virtue of the authorization may be made with a maximum of the total number of shares and warrants that may be issued without amendment to the articles of association adopted at any time by the general meeting.

The authorization is intended to be used, among other things, to carry out the rights issue of units that the board of directors intends to resolve upon in accordance with the Company’s press release on 10 October 2024, which enables the Company’s continued technical development of LaminarPace® as well as further business development. The reason for why new issues of shares and warrants by virtue of the authorization may be made with deviation from the shareholders’ pre-emption rights is to enable the Company to pay guarantee compensation in the form of units to guarantors who provide guarantee undertakings in the rights issue that the board of directors intends to resolve on pursuant to the authorization.

About Ziccum

Bulletin from the extraordinary general meeting of Ziccum

Analyst interview in Swedish with Ziccum’s CEO following the release of Q3, 2024 report

Watch Ziccum’s CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid in Swedish on the highlights of Ziccum’s Q3 2024 report and the company’s current status.

Ziccum’s CEO, Ann Gidner, shares a number of exciting developments, including an invitation to participate in a large international consortium with key industrial and academic partners, the on-going inhaled mRNA/LNP animal studies, and the current status of the collaboration with ReCode Therapeutics.

Please watch the entire interview here: https://youtu.be/5fUJ-wSJGX8

About Ziccum

Analyst interview in Swedish with Ziccum's CEO following the release of Q3, 2024 report

Three significant Ziccum patent families to be published

The three Ziccum AB (publ) (‘Ziccum’) patent application families advanced to international Patent Cooperation Treaty (PCT) stage in April 2024 will now be published. As of 31 October 2024, the PCT applications will be available for consultation worldwide. This constitutes another important step in Ziccum’s intellectual property development program for its LaminarPace® technology.

The specific Ziccum strategy for intellectual property (IP) is a multi-layered approach to cover and protect the full range of Ziccum’s innovations. It consists of patents, trademarks and know-how. The international Patent Cooperation Treaty (PCT) patent applications to be published now are addressing three different perspectives of the unique LaminarPace® processing and its results, to generate several layers of protection. The three fields are as follows.

1) ‘SYSTEMS FOR DRYING OF COMPOSITIONS AND RELATED METHODS’
covering substantial equipment development for the LaminarPace® unit.

This application, covering new equipment configurations in the LaminarPace® drying unit, has the largest scope including 50 claims. It covers numerous modifications in design and operational mode, for example enabling higher nebulization rates to increase production capacity. It also covers a vast number of additional equipment principles and fine optimizations performed during years of development of the LaminarPace® unit at Ziccum.

2) ‘DRYING OF COMPOSITIONS’
covering optimized parameters for LaminarPace® processing.

The second application is detailing the best process parameters for optimal LaminarPace® processing, based on valuable learnings in the Ziccum master plan work since 2022, learning from the interaction of equipment, formulations and process parameters. It is an important extra level of protection and secures the Ziccum position carrying unique knowledge of how to apply the LaminarPace® technology for the best pharmaceutical product quality and attributes.

3) ‘NANOPARTICLE FORMULATIONS’
covering formulations that are optimized for LaminarPace® drying.

This application covers new aspects of Ziccum’s formulation expertise, specifically for LaminarPace® applications. Lipid nanoparticle (LNP) formulation is the preferred formulation type in the growing field of (m)RNA development for new therapeutics and vaccines. Ziccum has gained extensive knowledge in the complex LNP formulation field in several studies during 2023 and 2024, confirming excellent results both in-vitro and in-vivo. This patent application covers these data sets as well as formulation knowledge also in a broader sense.

Ann Gidner CEO: “It is impressive how we have executed on our new strategy and master plan, both taking the LaminarPace unit much further towards completion and final design and generating strong data packages for new valuable targets. We are proud to include this new knowledge built for all these patent perspectives. Also, we are generating further data for a new patent application in planning.”

About Ziccum

Three significant Ziccum patent families to be published

Ziccum AB (publ) Interim report Q3 2024

INTERIM REPORT Q3, 1 JULY – 30 SEPTEMBER 2024

Significant events after Q3 2024

Ziccum intends to resolve on a rights issue of approximately SEK 30 million and raises a bridge loan

On October 10, The Board of Directors of Ziccum AB (publ) (“Ziccum” or the “Company”) announced its intention to carry out a new issue of shares and warrants (“Units”) with pre-emption rights for the Company’s shareholders (the ”Rights Issue”). The Board of Directors intends to publish a notice to an extraordinary general meeting planned to be held on 8 November 2024, to grant the Board of Directors an authorization to resolve on the Rights Issue and for the adoption of new articles of association. Each Unit consists of one (1) share and one (1) warrant free of charge of series TO 6 (“Warrants”). Upon full subscription in the Rights issue, the Company will initially receive approximately SEK 30 million in issue proceeds before issue costs. In connection with the Rights Issue, the Company has received subscription and guarantee undertakings amounting up to a total of approximately SEK 11.6 million, corresponding up to approximately 39 percent of the Rights Issue. The issue proceeds will primarily be used to further the technological development of LaminarPace®. To secure the Company’s liquidity needs until the completion of the Rights Issue, the Company has secured a SEK 6.5 million bridge loan from VIFC Nordic AB and Dariush Hosseinian.

Significant events during Q3 2024

Ziccum investigates significant increase in mRNA activity achieved with LaminarPace®

On August 16, Ziccum AB (publ) announced important findings on an increase in mRNA drug activity after LaminarPace® treatment and the investigations of the potential mechanisms behind this effect, including the development of a new, unique analytical method to generate further proof for this effect.

Ziccum announces trademarking LaminarPace in the USA

On 16 September, Ziccum announced that the appellation of its proprietary technology, LaminarPace, has been officially registered with the United States Patent and Trademark Office (USPTO) as a trademark since 23 July 2024. Obtaining trademark protection in the US, a market of primary importance to Ziccum, is a significant step in light of Ziccum’s growing industry presence, recognition as a commercial partner of choice, and Ziccum’s continuous scientific progress.

Ziccum announces outcome of exercise of warrants of series TO5

On September 17, Ziccum AB (publ) (”Ziccum” or the ”Company”) announces the outcome of the exercise of warrants of series TO5 (the ”Warrants”), which were issued in connection with the Company’s rights issue of units that ended in February 2024. In total, 23,880 Warrants, corresponding to approximately 2.53 percent of the number of outstanding Warrants, were exercised for subscription of 23,880 shares at an exercise price of SEK 4.91 per share. Through the exercise of the Warrants, Ziccum will receive approximately SEK 117,000 in issue proceeds before issue costs.

Ziccum announces change of Certified Adviser to Vator Securities

On September 26, Ziccum announced that the company has retained Vator Securities AB (“Vator Securities”) to serve as its Certified Adviser. The appointment of Vator Securities as Ziccum's Certified Adviser (CA) shall come into effect on September 27, 2024.

Significant events during Q2 2024

Ziccum strengthens and streamlines business and finance functions
On April 3, the company announced that it is reorganizing its administrative functions, due to the increased amount of business dialogues and to perform financial reporting in a more streamlined fashion. Two new roles of Business & Project Manager and a business-oriented, junior Financial Manager are introduced while the CFO role is eliminated.

Ziccum CEO to present at first annual event for Biopharma/Biotech Disruptors hosted by major US bank in New York City
On April 10, the company announced that on Tuesday May 14th, in New York City, Ziccum CEO Ann Gidner will present at the first event on high-value biotech and biopharma disruptor technologies to be hosted by CapitalOne, one of the US’ largest bank corporations. She will present as part of an expert panel regarding mRNA and gene therapeutics.
Ziccum contracts RFR Solutions for GMP manufacturing in next phase of technology scale-out
On April 26, the company announced that in addition to its existing network of high expertise suppliers and consultants, Ziccum has signed a long-term agreement with the GMP equipment specialist RFR Solutions, for the next phase in the industrialization and scale-out of the LaminarPace® equipment.
Ziccum AB strengthens patent portfolio with three solid data PCT applications according to expanded IP strategy
On April 30, the company announced that they have filed three PCT with ample and significant data covering years of equipment development and refinement, process parameter knowledge gained, plus key biopharmaceutical formulation expertise established. These various perspectives provide multi-layered protection to the company’s unique drying technology LaminarPace®.
Ziccum partners with Dagens Industri for Investor Relations program
On May 28, the company announced that they partner with Dagens Industri, the largest Nordic business paper, to improve shareholders’ access to news updates and raise broader awareness of its continuous scientific and commercial progress.
Exercise of employee stock options of series LTI 2021:1 at Ziccum AB (publ)
On June 3, the company announced on 27 April 2021, the Annual General Meeting of Ziccum AB (publ) ("Ziccum" or the "Company") resolved on a directed issue of not more than 46,000 employee stock options of series LTI 2021:1 (the "Stock Options") to certain employees and consultants in the Company. Today, Ziccum announces that 14,819 warrants of series 2021/2024 (the "Warrants"), related to LTI 2021:1, have been exercised for subscription of 23,709 new shares in the Company.
Ziccum reports on developments in the portfolio of industry partner projects
On June 11, the company announced that Ziccum is continuously engaged in business discussions with potential industrial partners. The status of Ziccum’s project portfolio is presented quarterly in the company interim reports. There are currently further updates to report.
Ziccum signs Evaluation agreement with ReCode Therapeutics for LaminarPace® mRNA study
On June 19, Ziccum AB signed an Evaluation Agreement with ReCode Therapeutics, Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, for evaluation of LaminarPace® enabling dry powder forms of ReCode’s proprietary therapeutic modalities.
Ziccum calls for a second investment tranche in accordance with its financing agreement with GCF
On June 25, the board of directors of Ziccum AB (publ) (“Ziccum” or the “Company”) called for a second investment tranche in accordance with the previously communicated financing agreement between the Company and Global Corporate Finance (“GCF”), and in connection therewith resolved to carry out a directed share issue.

Significant events during Q1 2024

Successful outcomes of LaminarPace® Feasibility study with Biotech partner
On January 10, the company announced that, together with its Biotech Corporation collaboration partner, it has reviewed the outcomes of the LaminarPace®. Feasibility study of mRNA/LNP materials under the agreement signed on May 9th, 2023. The study was very successful, and both parties confirmed consistent, positive readouts in the Study’s major parameters.
Financing secured through directed share issue and rights issue

On January 22, the company announced that it has carried out a directed share issue of 622,371 shares of approximately MSEK 4.2 to the American professional investor Global Corporate Finance (GCF).

The Directed New Share Issue is part of a long-term financing arrangement with GCF under which Ziccum has the unilateral right to call for additional investments from GCF, in exchange for newly issued shares, totaling approximately MSEK 28 over the next thirty months.

The Board of Directors of Ziccum has also, based on the existing authorization from the Annual General Meeting, decided to carry out a Rights Issue of units of a maximum of MSEK 10.4.

Considering the Directed New Share Issue, and provided that the Rights Issue is fully subscribed, Ziccum will receive initial proceeds totaling approximately MSEK 13.5.

Ziccum has proven excellent mRNA activity in animal study with LaminarPace® material
On January 31, the company announced that it has performed an animal study, confirming excellent genetic activity of mRNA/LNP materials treated by LaminarPace®. The in-vivo data confirms the ability of Ziccum’s LaminarPace® technology to transform delicate mRNA/LNP liquid solution into stable dry powder form, now proving the preserved mRNA activity also in animal testing. Assessing the mRNA effect in animal trials is a significant step for Ziccum.

Ziccum’s CEO Ann Gidner in Fireside Chat on mRNA development hosted by US Force Family Office

On February 12, the company announced that based on the growing reputation that Ziccum is building in the international pharmaceutical industry, Ziccum CEO Ann Gidner has taken part in a recorded Fireside Chat reviewing the mRNA arena, its tremendous growth, and the shortcomings of the RNA/LNP technology which can be addressed by treatment with the Ziccum technology LaminarPace®.

Ziccum announces outcome in rights issue

On February 16, the company announced the outcome of the rights issue of units, consisting of shares and warrants, which ended on 14 February 2024 (the ”Rights Issue”). The Rights Issue has been subscribed to a total of approximately 61.5 percent, of which approximately 58.6 percent was subscribed with unit rights and approximately 2.9 percent was subscribed without unit rights. Through the Rights Issue, Ziccum thus receives approximately MSEK 6.4 before issuing costs.

Ziccum reports significant progress in 3D-modelling project with model completion

On March 1, the company announced that Ziccum AB and project partner Zurich institute of Applied Sciences (ZHAW) have made a milestone review of the LaminarPace® simulation (LaPaSim) project progress and findings. The complex, dynamic model digitally replicating the LaminarPace® operation has been created and validated against comprehensive data sets created in physical trial runs and is now reaching a stage close to full completion. Ziccum can now perform trial runs in the 3D simulation environment, enabling the generation of vast amounts of data and in-depth understanding of optimal parameters and scale-out.

Ziccum inhalable mRNA/LNP project confirms excellent properties obtained by LaminarPace®

On March 14, the company announced that it has generated very good findings in the first stages of its collaborative project to engineer inhalable mRNA/LNP together with the University of Copenhagen. The results demonstrate that LaminarPace® successfully produces inhalable particles with special, desirable properties. The project will continue with in-vivo studies comparing inhalation versus injection.

CEO statement

Sharpening our focus and executing intensively on new abilities

Based on the generation of strong, extensive data with LaminarPace for mRNA in lipid formulations, we have validated an excellent position for this top development target. With such clear results for this most fragile entity, we have a solid position to address all types of biopharmaceuticals with LaminarPace.

We have updated our strategic focus accordingly, to address biological therapeutics as well as vaccines. In this large field we zoom in on the complex, fragile RNAs, plus protein-based drugs and vaccines. The therapeutic applications of the revolutionary mRNA technology are advancing fast, and this offers perfect timing to get new technology introduced in early stages of drug development. Drug projects, so called therapies, are also a good fit with LaminarPace capacity. This focus on the highest possible value for Ziccum, is complemented with a continued focus for new and better vaccines.

Proving LaminarPace for mRNA/LNP – even making inhalation possible

After proving excellent mRNA activity, both in partnered client studies and in our first animal trials, we are currently progressing with a more specialized animal study – the testing of inhaled mRNA/LNP. This is the sharpest edge of LaminarPace performance; no other technology has created inhalable mRNA/LNP so far.

In addition to the on-going project, engineering inhalable mRNA/LNP together with world-leading expertise, where the animal trials are just being completed, Ziccum has been invited to a new collaboration. A leading European institution was considering inhaled mRNA/LNP impossible – until seeing Ziccum present. A large international consortium is now in the works, to develop several mucosal applications of mRNA/LNP. All such applications require dry powder drug forms – which may be enabled by Ziccum technology. We look forward to announcing this when formalized.

For the topic of increased mRNA activity, the interesting work to understand the cellular mechanisms behind it is continuing, and we are preparing to add further patent protection for the valuable findings currently being generated.

Adding more partner projects for key clients

The project execution for ReCode Therapeutics with a specific mRNA/LNP therapeutic entity is just completed at Ziccum’s side. Resulting materials have been shipped to the client for assessment. As the potential benefits of dry powder forms of mRNA/LNP are significant for Recode, this client has asked Ziccum to present two more project offers – to ensure we evaluate the important potential. We are eager to look further into this.

Just after the quarter closing, we were happy to welcome a significant vaccine developer (Biotech Corp V) for a site visit in Lund, further assessing a collaboration and visiting our pilot facility. It is important to keep building the pipeline of dialogues. We are scheduling partnering meetings at the upcoming BIO-Europe conference for existing and new dialogues.

Executing on all the development projects, building intellectual property

The execution of Masterplan projects is continuously intense. In the recent period, the hardworking pilot team has generated LaminarPace materials for animal studies, process optimization work, nebulizer tests and the investigation of mRNA activity. This high capacity load is making it important to be careful about our client projects in parallel, selecting opportunities for the best near term and long term outcome.

The new expertise partnerships for optimizing the Ziccum-specific equipment components are rewarding, with good delivery of results while keeping strict budgets. The updated plan and new partner for the continuous processing project has enabled good savings on external costs. We will have a keen focus on this step in the Master plan in the quarter to come, and the 3D-modelling is a vital component.

The protection of immaterial rights is progressing, with an internal workshop for strategic planning held this quarter to ensure the best possible management. The international PCT patent families are taken forward and we are preparing for a next patent application based on new data.

Ensuring our solid progress ahead

To ensure the company’s financial foundation for continued development plans, the board of directors decided to propose a rights issue during fourth quarter to best serve Ziccum value and shareholder interests. In the current stock market climate it is not an easy feat, but initial proceedings already have generated good interest and secured new investors. We know we are building fantastic company value. Ziccum has generated solid proof for the disruptive technology possibilities, addressing the highest value market segment, and is pursuing collaborations with world-leading partners. We have the most interesting journey to take forward.

I want to extend my warmest gratitude to everyone involved in lots of enjoyable efforts – the team, our clients and partners, our owners and new investors, thank you!

Lund, October 29th, 2024

Ann Gidner

Operating income: kSEK 571 (2,329)
Result for the quarter: kSEK -5,887 (-3,882)
Earnings per share: SEK -0.37 (-0.28)
Cash flow for the quarter: kSEK -2,985 (-4,793)
Cash at the end of the reporting period: kSEK 1,107 (9,790)

Financial summary

	Jul-Sep	Jul-Sep	Jan-Sep	Jan-Sep	Jan-Dec
kSEK	2024	2023	2024	2023	2023
Operating income	571	2,329	4,186	4,743	6,318
Operating result	-5,924	-3,899	-17,563	-13,857	-21,560
Result	-5,887	-3,882	-17,491	-13,720	-21,412
Balance sheet total	9,848	21,764	9,948	21,764	14,972
Cash flow	-2,985	-4,793	-1,887	-13,161	-19,956
Cash and cash equivalents	1,107	9,790	1,107	9,790	2,994
Equity ratio %	26	73	26	73	57
Per share data (SEK)
Number of shares	15,958,775	13,806,142	15,958,775	13,806,142	13,806,142
Result per share before and after dilution*	-0.37	-0.28	-1.10	-0.99	-1.55
Cash flow per share	-0.19	-0.35	-0.12	-0.95	-1.45
Equity per share	0.16	1.51	0.16	1.51	0.62

* Dilution effect is not calculated when the result is negative

About Ziccum

Ziccum AB Q3 Report 2024

NEW NOTICE OF EXTRAORDINARY GENERAL MEETING IN ZICCUM AB (PUBL)

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.

N.B., Notice of the extraordinary general meeting of Ziccum AB (publ) on 8 November 2024 was published through a press release on 10 October 2024. For administrative reasons, it has been resolved to change the date of the announced extraordinary general meeting. The previous notice of the extraordinary general meeting is hereby withdrawn and the notice of a new extraordinary general meeting on 12 November 2024 is issued as follows, which does not contain any material changes compared to the previous one.

The shareholders of Ziccum AB (publ), reg. no. 559107-9412, (the “Company”) are hereby given notice to attend the extraordinary general meeting (the “EGM”) on 12 November 2024 at 12.00 CET at the Company’s premises at Scheelevägen 22 in Lund. Registration starts at 11.30 CET.

Right to participate
Shareholders that wish to participate in the EGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on 4 November 2024 and shall have notified the Company of their intention to participate at the EGM no later than on 6 November 2024. Notice to participate shall be given in writing by e-mail to ziccum@fredersen.se or by post to Ziccum AB (publ) c/o Fredersen Advokatbyrå, Neptunigatan 82, 211 18, Malmö. The notice shall contain the shareholder’s name, personal identity number or registration number and telephone number and, where applicable, the number of advisors (maximum two).

Nominee-registered shares
Shareholders whose shares are registered in the name of a nominee/custodian must register their shares in their own names in order to be entitled to participate in the EGM. Such registration, which may be temporary, must be effected no later than on 6 November 2024 and shareholders must, therefore, instruct their nominees well in advance thereof.

Proxy
If a shareholder wishes to be represented by proxy, a power of attorney shall be issued to the proxy. The power of attorney is to be in writing, dated and duly signed by the shareholder. If the shareholder is a legal entity, a certificate of incorporation or a corresponding document shall be included with the notification. Please provide the power of attorney in original as well as certificate of incorporation and other documents of authority to the Company to the address mentioned above well in advance before the EGM. If the power of attorney and other documents of authority have not been provided in advance, these documents must be presented at the EGM. Power of attorney forms are available at the Company and on the Company’s website, www.ziccum.com and will be sent upon request to any shareholder who states their postal address.

Proposal of agenda

Opening of the meeting
Election of chairman of the meeting
Preparation and approval of the voting register
Approval of the agenda
Election of one or two persons to attest the minutes
Determination as to whether the meeting has been duly convened
Resolution on amendment to the articles of association
Resolution on authorization for the board to resolve on issue of units etc.
Closing of the meeting

Proposals

Resolution on amendment of the articles of association (item 7)
At the time of the notice, there are a total of 15,958,775 shares outstanding in the Company. As part of the board of directors' intention to carry out a rights issue of units of approximately SEK 30 million, by virtue of the authorization proposed to be resolved on in accordance with item 8 in the agenda and as set out in the Company's press release on 10 October 2024, the board of directors proposes that the EGM resolves to amend the articles of association by adopting new limits for the share capital and the number of shares. Therefore, the board of directors has prepared four different proposals for amendments to the articles of association with regard to the limits for the share capital and the number of shares. The articles of association that are to be registered with the Swedish Companies Registration Office depends on how many units are subscribed for and paid in the rights issue that the Board of Directors intends to resolve on by virtue of the authorization proposed to be resolved on under item 8.

The board of directors, the CEO, or a person appointed by the board of directors is authorized, after the board of directors has resolved to carry out a rights issue of units, by virtue of the authorization proposed to be resolved pursuant to item 8, and after that rights issue has been completed and the outcome is known, to submit to the Swedish Companies Registration Office for registration the amendment of the articles of association that is best adapted to the outcome of the rights issue.

i) Amendment of the articles of association (alternative 1)
The board of directors proposes that the EGM resolves to amend the articles of association as follows.

The limits for the share capital in § 4 of the articles of association are proposed to be amended as follows: “The share capital shall be not less than SEK 2,500,000 and not more than SEK 10,000,000.”

Furthermore, it is proposed that the limits for the number of shares in § 5 of the articles of association be amended as follows: “The number of shares shall be not less than 15,000,000 and not more than 60,000,000.”

ii) Amendment of the articles of association (alternative 2)
The board of directors proposes that the EGM resolves to amend the articles of association as follows.

The limits for the share capital in § 4 of the articles of association are proposed to be amended as follows: “The share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000.”

Furthermore, it is proposed that the limits for the number of shares in § 5 of the articles of association be amended as follows: “The number of shares shall be not less than 30,000,000 and not more than 120,000,000.”

iii) Amendment of the articles of association (alternative 3)
The board of directors proposes that the EGM resolves to amend the articles of association as follows.

The limits for the share capital in § 4 of the articles of association are proposed to be amended as follows: “The share capital shall be not less than SEK 10,000,000 and not more than SEK 40,000,000.”

Furthermore, it is proposed that the limits for the number of shares in § 5 of the articles of association be amended as follows: “The number of shares shall be not less than 60,000,000 and not more than 240,000,000.”

iv) Amendment of the articles of association (alternative 4)
The board of directors proposes that the EGM resolves to amend the articles of association as follows.

The limits for the share capital in § 4 of the articles of association are proposed to be amended as follows: “The share capital shall be not less than SEK 20,000,000 and not more than SEK 80,000,000.”

Furthermore, it is proposed that the limits for the number of shares in § 5 of the articles of association be amended as follows: “The number of shares shall be not less than 120,000,000 and not more than 480,000,000.”

Further, the board of directors proposes some minor editorial changes and that the CEO, or the person appointed by them, is authorized to make the minor adjustments to the resolution that may prove necessary in connection with the registration of the articles of association with the Swedish Companies Registration Office.

The board of directors' proposal for resolution under this item 7 is conditional upon the EGM resolving to authorize the board of directors to resolve on a new issue of units under item 8.

Resolution on authorization for the board to resolve on issue of units etc. (item 8)
The board of directors proposes that the EGM resolves to authorize the board of directors to, during the period until the next annual general meeting and in addition to the authorization resolved upon at the annual general meeting 2024, on one or more occasions resolve on a new issue of shares and warrants. New issues of shares and warrants by virtue of the authorization may be made with or without deviation from the shareholders' pre-emption rights, against payment in cash, in kind or by way of set-off or otherwise on terms referred to in Chapter 2. Section 5, second paragraph, 1–3 and 5 of the Swedish Companies Act. Resolutions on new issues of shares and warrants by virtue of the authorization may be made with a maximum of the total number of shares and warrants that may be issued without amendment to the articles of association adopted at any time by the general meeting.

The authorization is intended to be used, among other things, to carry out the rights issue of units that the board of directors intends to resolve upon in accordance with the Company's press release on 10 October 2024, which enables the Company to finance the expansion of the Company's technologies and the Company's technical development of LaminarPace®. The reason for why new issues of shares and warrants by virtue of the authorization may be made with deviation from the shareholders' pre-emption rights is to enable the Company to pay guarantee compensation in the form of units to guarantors who provide guarantee undertakings in the rights issue that the board of directors intends to resolve on pursuant to the authorization.

The CEO, or the person appointed by the CEO, shall be authorized to make such minor adjustments to the resolution as may be required for the purposes of registration and execution.

The board of directors' proposal for resolution under this item 8 is conditional upon the EGM resolving to amend the articles of association under item 7.

Majority requirements
Resolutions in accordance with items 7 and 8 above require approval of at least two thirds (2/3) of the shares represented and votes cast at the EGM.

Further information
At the time of publication of this notice, the total number of shares and votes in the Company are 15,958,775. The Company does not hold any own shares.

Proxy forms and other documents related to the EGM will be available at the Company and on the Company’s website at least three weeks before the EGM. The documents will be sent to shareholders who request it and who provide their postal address.

The shareholders are reminded of their right of information according to Chapter 7, Section 32 of the Swedish Companies Act.

The Company has its registered office in Lund.

Processing of personal data
For information on how your personal data is processed, see:
https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

Lund, October 2024
Ziccum AB (publ)
The Board of Directors

About Ziccum

NEW NOTICE OF EXTRAORDINARY GENERAL MEETING IN ZICCUM AB (PUBL)

1 2 3 4 5 … 30 31 32

Posts navigation